Jazz Pharmaceuticals PLC

JAZZ77

$126.67arrow_drop_up1.21%$1.52

JAZZ77

$126.67

arrow_drop_up1.21%$1.52

Performance History

Key Stats
Open	$125.76
Prev. Close	$125.10
EPS	7.06
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

	LOW	HIGH
Day Range	124.14	127.75
52 Week Range	99.06	137.39

Ratios







EPS	7.06

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Jazz Pharmaceuticals PLC (JAZZ)

Jazz Pharmaceuticals PLC (JAZZ) is a biopharmaceutical company focused on developing and commercializing innovative medicines in the therapeutic areas of sleep and hematology/oncology. The company's mission is to improve patients' lives by transforming medical science into life-changing medicines. Jazz Pharmaceuticals is known for its commitment to innovation and its track record of successfully bringing new treatments to market. The company's portfolio includes a diverse range of products, including Xyrem, Vyxeos, and Erwinaze, among others.

Jazz Pharmaceuticals has a strong market position in its focus areas, with a market capitalization of over $9 billion. The company's stock price has shown steady growth over the years, reflecting investors' confidence in its ability to deliver value. In addition, Jazz Pharmaceuticals has a positive PEG ratio, indicating that the stock is undervalued relative to its expected earnings growth. The company's financial performance is also strong, with robust revenue and earnings growth in recent years.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Bruce C. Cozadd
Headquarters: Dublin
Employees: 2800
Exchange: NASDAQ

add Jazz Pharmaceuticals PLC to watchlist

Keep an eye on Jazz Pharmaceuticals PLC

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Jazz Pharmaceuticals PLC's (JAZZ) price per share?

The current price per share for Jazz Pharmaceuticals PLC (JAZZ) is $126.67. The stock has seen a price change of $1.52 recently, indicating a 1.22% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Jazz Pharmaceuticals PLC (JAZZ)?

For Jazz Pharmaceuticals PLC (JAZZ), the 52-week high is $137.39, which is 8.46% from the current price. The 52-week low is $99.06, the current price is 27.87% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Jazz Pharmaceuticals PLC (JAZZ) a growth stock?

Jazz Pharmaceuticals PLC (JAZZ) has shown an average price growth of -4.13% over the past three years. It has received a score of 47 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Jazz Pharmaceuticals PLC as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Jazz Pharmaceuticals PLC (JAZZ) stock price performance year to date (YTD)?

As of the latest data, Jazz Pharmaceuticals PLC (JAZZ) has a year-to-date price change of -0.2%. Over the past month, the stock has experienced a price change of 13.98%. Over the last three months, the change has been 11.24%. Over the past six months, the figure is 21.87%. Looking at a longer horizon, the five-year price change stands at -14.22%.

help

Is Jazz Pharmaceuticals PLC (JAZZ) a profitable company?

Jazz Pharmaceuticals PLC (JAZZ) has a net income of $414.83M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 88.64% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 24.67% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $3.83B, with a revenue growth rate of 4.78%, providing insight into the company's sales performance and growth. The gross profit is $3.4B. Operating income is noted at $578.58M. Furthermore, the EBITDA is $1.33B.

help

What is the market capitalization of Jazz Pharmaceuticals PLC (JAZZ)?

Jazz Pharmaceuticals PLC (JAZZ) has a market capitalization of $7.66B. The average daily trading volume is 126.44, indicating the stock's liquidity and investor engagement.

News

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Zymeworks Announces Participation in Upcoming Investor Conferences